Effects of Nicotinic Acid and Sevelamer on Hyperphosphatemia in the Hemodialysis Patients: A Double Blind Clinical Trial

Control of the phosphorus in dialysis’ patients is very important and can be done in many ways. The purpose of the study is to determine the effect of Nicotinic acid (Niacin) and Sevelamer on the serum phosphorus of hemodialysis patients. This double-blind randomized clinical trial study includes two groups: 60 patients (taking Niacin) and 60 patients control groups (taking Sevelamer).Niacin dose was increasing monthly in three steps from 200 to 600 mg and Sevelamer from 400 to 1200 mg. Serum phosphorus was measured in the both groups and the results were compared. In this study P<0.05 was significant. A total of 120 patients attending in this study, mean age of case group were 51.5± 21.3 years and control group was 50.7± 22.5 years that no have difference. Phosphor level in starter study in case group was 6.67±1.37 mg/dl and control group was 6.77±0.95 mg/dl that no has difference. Niacin significantly decreased the blood phosphorus levels (P<0.001) that with increasing the dose of niacin, this decreasing was more than Sevelamer. Nicotinic acid can decrease serum phosphorous; however, it is need a longer trial study for determining the most effective doses of the Nicotinic acid.